The Push Precision OSA Care Needed
For years, individualized obstructive sleep apnea care has been more aspiration than routine practice. Pharmacologic therapies may help change that.
For years, individualized obstructive sleep apnea care has been more aspiration than routine practice. Pharmacologic therapies may help change that.
A post hoc analysis of the SELECT trial suggests that semaglutide 2.4 mg is associated with a significantly lower incidence of obstructive sleep apnea in adults with overweight or obesity and established cardiovascular disease. While these findings are promising, Novo Nordisk notes that semaglutide is not currently approved to treat obstructive sleep apnea and further research is required.
Research presented at ATS 2026 reveals that positional therapy conditions patients to avoid back-sleeping, maintaining obstructive sleep apnea control for up to a year after device withdrawal.
What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?
The acquisition of PONM gives Nexalin ownership of the AI-integrated software supporting its HALO Clarity program, preparing for a 160-participant trial for moderate-to-severe insomnia.
The medical technology company is transitioning leadership to focus on its next phase of growth and commercial traction for its obstructive sleep apnea therapy in the US market.
The new dual-product system aims to support the 24-hour wellness cycle, accompanied by a strategic partnership with the Calm app to offer curated sleep content.
A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.
A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.